Drug intelligence / Profile preview

UniFluVec

Development stage: Phase 1
Lead developer: Capricorn Technologies
Modality: Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intranasal

Overview

UniFluVec is a universal influenza vector vaccine being developed for prophylaxis against various influenza types and subtypes. It is an attenuated vaccine that functions as an immunostimulant. The vaccine is administered intranasally and has demonstrated full attenuation in ferrets, causing no clinical symptoms, weight loss, or fever when administered at a dose of 7.8 log10 EID50/animal. Studies have shown that UniFluVec provides heterosubtypic protection against influenza viruses, with a single immunization showing comparable efficacy to double vaccination and superior protection compared to control viruses with intact NS genomic segments.

Brand names: UniFluVec

Beyond the preview

Go deeper on UniFluVec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UniFluVec.

Explore the full profile